JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Current Portion of Long-Term Debt
JW (Cayman) Therapeutics Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitive Current Portion of Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Current Portion of Long-Term Debt
¥20.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Current Portion of Long-Term Debt
¥358.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Current Portion of Long-Term Debt
¥1.2B
|
CAGR 3-Years
65%
|
CAGR 5-Years
161%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Current Portion of Long-Term Debt
¥13.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Current Portion of Long-Term Debt
¥46.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Current Portion of Long-Term Debt
¥11.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
20.2m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Current Portion of Long-Term Debt amounts to 20.2m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-14%
Over the last year, the Current Portion of Long-Term Debt growth was 0%. The average annual Current Portion of Long-Term Debt growth rates for JW (Cayman) Therapeutics Co Ltd have been 23% over the past three years , -14% over the past five years .